Abionyx Pharma Stock Jumps After Stifel Initiates Coverage with 'Buy' Rating

Shares of Abionyx Pharma (ABNX) climbed 6.8% to €1.818 in trading today after financial services firm Stifel initiated coverage on the stock with a "Buy" rating. The firm set a price target of €8.50, which suggests a potential upside of nearly 400% from the stock's Wednesday closing price of €1.70.

Stifel's Bullish Thesis

In its research note, Stifel described Abionyx as a "near-term orphan opportunity with multiblockbuster sepsis upside." The positive outlook is centered on the company's main drug candidate, CER-001, which is being developed for two distinct medical needs:

• Sepsis: A potentially life-threatening response to infection, representing a major market opportunity.
• LCAT deficiency: An extremely rare genetic disease that currently has no approved treatment.

Stifel's analysis points to the dual potential of CER-001 to address both a large-scale critical care condition and a high-value rare disease, underpinning its high valuation target.

Clinical and Financial Outlook

Ad

The initiation comes ahead of key clinical milestones for Abionyx. The company expects to begin a Phase 2b trial for CER-001 in sepsis during the fourth quarter, with initial data anticipated in the first half of 2028. For the LCAT deficiency indication, a marketing-authorization filing is targeted for 2028.

Abionyx will release its half-year 2026 earnings on September 24. A late-August corporate update showed a consolidated cash and equivalents position of €26.9 million as of June 30, 2026, providing the company with financial visibility through the end of 2028.

Market Context

The stock's advance was also supported by a broader risk-on sentiment in the market, with major indices trading higher. This positive backdrop often benefits more speculative, small-cap biotechnology stocks. Trading near its 52-week low of €1.66 prior to the news, Abionyx's stock was particularly responsive to the new analyst coverage and subsequent buying activity.